Aspirin vs P2Y12 inhibitors
How to tell Aspirin and P2Y12 inhibitors apart when a board question makes them look alike.
Aspirin: irreversibly blocks platelet COX-1 and thromboxane A2; P2Y12 inhibitors (clopidogrel, ticagrelor): block the platelet ADP receptor.
Side by side
Irreversible platelet COX inhibition lowers thromboxane A2 for the platelet lifespan.
Clopidogrel, prasugrel, or ticagrelor block platelet ADP P2Y12 signaling, commonly paired with aspirin after coronary stenting.
Aspirin acetylates platelet cyclooxygenase, blocking thromboxane-mediated platelet activation.
P2Y12 inhibition prevents ADP-driven platelet activation and aggregation.
Aspirin: an irreversible antiplatelet that prolongs bleeding time without changing PT or PTT, recovers only with new platelet production over 7 to 10 days, dosed 81 mg daily for prevention or 325 mg for ACS loading, and remains the workhorse for primary and secondary cardiovascular prevention. Reye syndrome is the high-yield contraindication in children with viral illness.
P2Y12 inhibitor: an antiplatelet given as dual therapy after coronary stenting that requires CYP2C19 activation (clopidogrel 75 mg, reduced efficacy in poor metabolizers), or potent prodrug activation (prasugrel 10 mg, avoid with prior stroke), or reversible direct binding (ticagrelor 90 mg twice daily, with dose-related dyspnea and uric acid elevation).
The trap
Both are antiplatelet drugs used in coronary disease, so the receptor/mechanism clue matters.
The repair move
Name the platelet step the drug blocks before choosing. Aspirin kills thromboxane A2 production at 81 mg daily for prevention or 325 mg loading dose for ACS. Clopidogrel and prasugrel are prodrugs needing CYP activation that irreversibly block P2Y12; prasugrel is faster and not affected by CYP2C19 polymorphisms but is contraindicated after prior stroke or TIA. Ticagrelor reversibly blocks P2Y12 without prodrug activation and causes dose-related dyspnea. Cangrelor is IV-only for the cath lab. After PCI, dual antiplatelet therapy is aspirin plus a P2Y12 inhibitor for 6 to 12 months.
Try a free question
CoreA patient with acute coronary syndrome receives a drug that irreversibly inhibits platelet cyclooxygenase and decreases thromboxane A2. Which antiplatelet is this?
Show answer and explanation
Answer: A. Aspirin. Aspirin irreversibly inhibits platelet COX, reducing thromboxane A2 for the platelet lifespan.
Why the other choices are tempting
- B. Clopidogrel blocks the P2Y12 ADP receptor.
- C. Ticagrelor also blocks P2Y12 but is reversible and not a prodrug in the same way.
- D. Warfarin is an anticoagulant that reduces vitamin K-dependent clotting factors.
- E. Heparin activates antithrombin and is not an antiplatelet COX inhibitor.
Flashcards
Tap a card to flip it.
What is the fastest separator for Aspirin vs P2Y12 inhibitors?
Aspirin: irreversibly blocks platelet COX-1 and thromboxane A2; P2Y12 inhibitors (clopidogrel, ticagrelor): block the platelet ADP receptor.
What clue should make you choose Aspirin?
Irreversible platelet COX inhibition lowers thromboxane A2 for the platelet lifespan.
Quick answers
What is the fastest way to tell Aspirin from P2Y12 inhibitors?
Aspirin: irreversibly blocks platelet COX-1 and thromboxane A2; P2Y12 inhibitors (clopidogrel, ticagrelor): block the platelet ADP receptor.
What is the key clue for Aspirin?
Irreversible platelet COX inhibition lowers thromboxane A2 for the platelet lifespan.
What is the key clue for P2Y12 inhibitors?
Clopidogrel, prasugrel, or ticagrelor block platelet ADP P2Y12 signaling, commonly paired with aspirin after coronary stenting.
What is the common trap with Aspirin vs P2Y12 inhibitors?
Both are antiplatelet drugs used in coronary disease, so the receptor/mechanism clue matters.